恩赛特韦治疗 COVID-19 奥密克戎变异株导致的医护人员咳嗽的疗效。
Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers.
机构信息
First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, Hirakata, Japan.
Department of Emergency Medicine, Kansai Medical University Medical Center, Moriguchi, Japan.
出版信息
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0106424. doi: 10.1128/aac.01064-24. Epub 2024 Aug 29.
Abstract
We evaluated the efficacy of ensitrelvir for the treatment of cough due to coronavirus disease 2019 Omicron variant in medical healthcare workers. A total of 633 patients were registered in this study: 206 patients chose ensitrelvir and 427 patients chose symptomatic treatment. Difference in score changes using the Leicester Cough Questionnaire between groups was 3.17 on day 4, 3.24 on day 7, and 2.46 on day 14. The analysis demonstrated a significant difference at all time points.
摘要
我们评估了恩赛特韦在治疗因新冠病毒奥密克戎变异株感染而引起的咳嗽方面的疗效。共有 633 名医护人员参与了这项研究：206 名患者选择了恩赛特韦，427 名患者选择了对症治疗。莱斯特咳嗽问卷评分的组间变化差异在第 4 天为 3.17，第 7 天为 3.24，第 14 天为 2.46。分析表明所有时间点均存在显著差异。
相似文献
1
Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers.恩赛特韦治疗 COVID-19 奥密克戎变异株导致的医护人员咳嗽的疗效。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0106424. doi: 10.1128/aac.01064-24. Epub 2024 Aug 29.
2
The time to return-to-work in healthcare workers with COVID-19 treated with ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2: An observational study utilizing pre-existing data from a single hospital.使用新型口服 SARS-CoV-2 3C 样蛋白酶抑制剂恩西瑞韦治疗的 COVID-19 医护人员的复工时间：一项利用单家医院现有数据的观察性研究
J Infect Chemother. 2025 Apr;31(4):102669. doi: 10.1016/j.jiac.2025.102669. Epub 2025 Feb 27.
3
Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.恩西他韦治疗非住院成人新冠肺炎：3期随机双盲安慰剂对照试验SCORPIO-HR的结果
Clin Infect Dis. 2025 Jul 18;80(6):1235-1244. doi: 10.1093/cid/ciaf029.
4
Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CL detected in the SCORPIO-SR phase 3 trial.在SCORPIO-SR 3期试验中检测到的新冠病毒3CL中恩西他韦治疗引发的氨基酸替代。
Antiviral Res. 2025 Apr;236:106097. doi: 10.1016/j.antiviral.2025.106097. Epub 2025 Jan 30.
5
Comparative study of ensitrelvir and symptomatic therapy in healthcare workers with mild COVID-19: A single center retrospective analysis in Chiba, Japan.恩昔瑞韦与对症治疗在轻度新型冠状病毒肺炎医护人员中的对比研究：日本千叶的一项单中心回顾性分析
J Infect Chemother. 2025 Apr;31(4):102668. doi: 10.1016/j.jiac.2025.102668. Epub 2025 Feb 26.
6
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦/利托那韦片用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.
7
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.西帕维巴特用于预防免疫功能低下个体的COVID-19的疗效和安全性（SUPERNOVA）：一项随机、对照、双盲、3期试验。
Lancet Infect Dis. 2025 Jul;25(7):813-826. doi: 10.1016/S1473-3099(24)00804-1. Epub 2025 Feb 24.
8
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.SARS-CoV-2 中和单克隆抗体预防 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2.
9
Effectiveness of ensitrelvir for cough caused by COVID-19 Omicron variant in patients with asthma.恩西他韦对哮喘患者中由新冠病毒奥密克戎变异株引起的咳嗽的疗效。
Microbiol Spectr. 2025 Apr 15;13(5):e0340724. doi: 10.1128/spectrum.03407-24.
10
The effect of sample site and collection procedure on identification of SARS-CoV-2 infection.样本采集部位和采集程序对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染鉴定的影响。
Cochrane Database Syst Rev. 2024 Dec 16;12(12):CD014780. doi: 10.1002/14651858.CD014780.
引用本文的文献
1
Effectiveness of ensitrelvir for cough caused by COVID-19 Omicron variant in patients with asthma.恩西他韦对哮喘患者中由新冠病毒奥密克戎变异株引起的咳嗽的疗效。
Microbiol Spectr. 2025 Apr 15;13(5):e0340724. doi: 10.1128/spectrum.03407-24.
本文引用的文献
1
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.口服恩赛特韦 5 天治疗轻中度 COVID-19 患者的疗效和安全性：SCORPIO-SR 随机临床试验。
JAMA Netw Open. 2024 Feb 5;7(2):e2354991. doi: 10.1001/jamanetworkopen.2023.54991.
2
Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study.日本基于登记的观察性研究：COVID-19 症状与奥密克戎亚变体 BA.2 和 BA.5、宿主状态和临床结局的关联。
Lancet Infect Dis. 2023 Nov;23(11):1244-1256. doi: 10.1016/S1473-3099(23)00271-2. Epub 2023 Jun 30.
3
Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.恩赛特韦在轻至中度 2019 冠状病毒病患者中的疗效和安全性：一项随机、安慰剂对照、2/3 期研究的 2b 期部分。
Clin Infect Dis. 2023 Apr 17;76(8):1403-1411. doi: 10.1093/cid/ciac933.
4
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.一项评估新型口服 SARS-CoV-2 3CL 蛋白酶抑制剂恩赛特韦（ensitrelvir）在日本轻至中度 COVID-19 或无症状 SARS-CoV-2 感染患者中的疗效和安全性的随机 2/3 期研究：2a 期部分结果。
Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0069722. doi: 10.1128/aac.00697-22. Epub 2022 Sep 13.
5
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.奥密克戎 BA.2 型 SARS-CoV-2 的特征和抗病毒敏感性
Nature. 2022 Jul;607(7917):119-127. doi: 10.1038/s41586-022-04856-1. Epub 2022 May 16.
6
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.S-217622 的发现：一种非共价的口服 SARS-CoV-2 3CL 蛋白酶抑制剂临床候选药物，用于治疗 COVID-19。
J Med Chem. 2022 May 12;65(9):6499-6512. doi: 10.1021/acs.jmedchem.2c00117. Epub 2022 Mar 30.
7
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
8
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
9
Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.冠状病毒 3C 样蛋白酶抑制剂在开发新型抗 SARS-CoV-2 药物中的潜力：来自蛋白酶和抑制剂结构的见解。
Int J Antimicrob Agents. 2020 Aug;56(2):106055. doi: 10.1016/j.ijantimicag.2020.106055. Epub 2020 Jun 11.
10
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
Zotero 插件